Krasivskyi Ihor, Ivanov Borko, Vehrenberg Johannes, Eghbalzadeh Kaveh, Gerfer Stephen, Gaisendrees Christopher, Kuhn Elmar, Sabashnikov Anton, Mader Navid, Djordjevic Ilija, Wahlers Thorsten
Department of Cardiothoracic Surgery, University Hospital Cologne, 50937 Cologne, Germany.
Department of Cardiothoracic Surgery, Helios Hospital Siegburg, 53721 Siegburg, Germany.
Life (Basel). 2022 Oct 31;12(11):1746. doi: 10.3390/life12111746.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) represents an increasingly used method for circulatory support. Despite the ongoing research, survival following VA-ECMO therapy remains low. Sex-related differences might impact the outcome of therapeutic measures. We aimed to compare all-cause mortality among female and male patients who underwent VA-ECMO as a bridge to recovery investigating sex-related differences. From January 2015 until August 2020, 87 patients were supported by VA-ECMO as a part of our out-of-center mobile ECMO program. In order to analyze sex-associated differences in early clinical outcomes, patients were divided into two sex categories: men ( = 62) and women ( = 25). All relevant data (in-hospital mortality, ICU and hospital stay, renal failure requiring dialysis, lung failure, bleeding, stroke and septic shock) were analyzed retrospectively after the extraction from our institutional database. Mean age of the study population was 53 ± 14 years. Mean EuroSCORE II predicted mortality was 6.5 ± 3.7. In-hospital mortality rate was not significantly lower in the female group (58.3%) vs. the male group (71.2%), = 0.190. The mean length of ICU and hospital stay was 9 ± 11 in the male group vs. 10 ± 13 in the female group, = 0.901, and 10 ± 12 (male group) vs. 11 ± 13 (female group), = 0.909, respectively. Renal failure requiring hemodialysis (36.2% (males) vs. 28.6% (females), = 0.187) was comparable between both groups. Respiratory failure was diagnosed in 31 (56.4%) male vs. 8 (34.8%) female patients, = 0.068, while 16 (28.6%) male vs. 3 (13.0%) female patients ( = 0.118) suffered from septic shock. Based on our data, there were no sex-specific outcome discrepancies in patients treated with mobile VA-ECMO implantation.
静脉-动脉体外膜肺氧合（VA-ECMO）是一种越来越常用的循环支持方法。尽管研究仍在进行，但VA-ECMO治疗后的生存率仍然很低。性别差异可能会影响治疗措施的结果。我们旨在比较接受VA-ECMO作为恢复桥梁的女性和男性患者的全因死亡率，以研究性别差异。从2015年1月到2020年8月，87名患者接受了VA-ECMO支持，这是我们中心外移动ECMO项目的一部分。为了分析早期临床结果中的性别相关差异，患者被分为两类：男性（n = 62）和女性（n = 25）。从我们的机构数据库中提取所有相关数据（院内死亡率、ICU和住院时间、需要透析的肾衰竭、肺衰竭、出血、中风和感染性休克）后进行回顾性分析。研究人群的平均年龄为53±14岁。欧洲心脏手术风险评估系统（EuroSCORE）II预测的平均死亡率为6.5±3.7。女性组的院内死亡率（58.3%）与男性组（71.2%）相比没有显著降低，P = 0.190。男性组的ICU和住院平均时间分别为9±11天和10±12天，女性组分别为10±13天和11±13天，P分别为0.901和0.909。两组间需要血液透析的肾衰竭发生率相当（男性为36.2%，女性为28.6%，P = 0.187）。31名（56.4%）男性患者和8名（34.8%）女性患者被诊断为呼吸衰竭，P = 0.068，而16名（28.6%）男性患者和3名（13.0%）女性患者（P = 0.118）患有感染性休克。根据我们的数据，接受移动VA-ECMO植入治疗的患者没有性别特异性的结果差异。
